Related Experiment Video
Updated: Feb 5, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs
Takashi Ogura1,2, Satoshi Morita2, Kan Yonemori3
11 Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Abstract:
During oncology drug development, it is important that ethnic differences are evaluated to determine the optimal dose and administration schedule in a new region based on the clinical data from other regions. The objective of this study was to explore the possibility of detecting ethnic differences in toxicity during early-phase clinical trials. Data were reviewed from phase I clinical trials for new drug applications conducted in Japan and Western countries. The maximum tolerated doses (MTDs), recommended phase II doses (RP2Ds), and approved doses in Japan were compared with those in Western countries. There were 4 of 28 drugs eligible for analysis that showed differences in MTDs or RP2Ds between Japanese and Western patients. Differences in MTDs or RP2Ds in 2 phase I trials were associated with ethnic differences in toxicity. It may be worthwhile to evaluate ethnic differences in toxicity during early-phase clinical trials for oncology drugs.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Drug Metabolism: Phase I Reactions
Drug Metabolism: Phase II Reactions
Ethnic Identity within a Larger Culture